Peptipedia
HealingPreclinicalAnimal Studies

KLOW Blend

Also known as KLOW Stack, KLOW Protocol, Advanced Healing Blend

An advanced multi-peptide blend described as evolution of the Glow stack with added KPV for enhanced anti-inflammatory and gut health benefits.

Preclinical Research (Components)
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

80mg total vial: GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg), TB-500 (10mg)

Frequency

Once daily

Duration

8-12 weeks

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 80mg total vial: GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg), TB-500 (10mg) via Subcutaneous injection, Once daily. Dose range: Per component ratios. Duration: 8-12 weeks.

Timing & Administration

Administer via Subcutaneous injection. Frequency: Once daily.

Mechanism of Action

Combines tissue repair properties from BPC-157 and TB-500 with skin benefits from GHK-Cu, plus KPV's potent anti-inflammatory action via NF-κB inhibition.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical Research (Components).

Side Effects & Safety

Important Warnings

  • Components individually restricted from compounding
Injection site reactions
mild fatigue initially
temporary GI changes
headache (rare)

References

No references available.

Related Peptides

Browse all →
BPC-157Healing

A synthetic peptide derived from a protein found in human gastric juice. Extensive preclinical studies demonstrate efficacy in healing tendons, ligaments, muscles, and the GI tract.

View profile
TB-500Healing

A synthetic 17-amino acid fragment of Thymosin Beta-4 with a longer half-life (~2-4 days) compared to the full protein (~2 hours).

View profile
LL-37Immune

A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.

View profile